Current Headlines

  1. TSRI’s MS Drug Also Shows Promise In Ulcerative Colitis
    10/30/2014

    The Scripps Research Institute (TSRI) reported that results from the Phase 2 study of RPC1063, a drug discovered at the Institute, show RPC1063’s potential in the treatment of ulcerative colitis (UC).

  2. Salk Scientists Identify Protein As HIV-1 Therapeutic Target
    10/30/2014

    A team of scientists from the Salk Institute for Biological Studies reported that they have identified a protein that could be exploited as HIV-1’s Achilles heel.

  3. GSK Expands Drug Research Partnership With Five Prime
    10/30/2014

    Five Prime Therapeutics, a clinical stage biotech firm, announced that its partner GlaxoSmithKline has extended their drug research collaboration in respiratory diseases for another year and a half.

  4. Cancer Innovation Coalition Seeks To Close Gap Between Development And Market
    10/30/2014

    The Cancer Innovation Coalition (CIC) convened its first national policy forum this week where researchers, government officials, and industry experts met to discuss methods of closing the gap between promising new therapies and cancer patients, Drug Discovery and Development (DDD) reports.

  5. PhosImmune, Pure MHC Collaborate To Develop New Cancer Immunotherapies
    10/29/2014

    Oncology biotech company PhosImmune has announced that it has entered into a license and collaboration agreement with Pure MHC, a subsidiary of PureProtein specializing in disease-specific target identification and drug discovery for cancer and other diseases.

  6. New Anti-Cancer Drug Shows Promising Results With Low Toxicity
    10/29/2014

    Researchers at the University of Chicago have reported ‘dramatic’ anti-cancer activity of a new drug, OTS964, which was able to completely eliminate aggressive human lung cancers transplanted into mice — and with minimal side effects.

  7. FDA Approves Baxter's Obizur For Acquired Hemophilia A
    10/29/2014

    Patients with acquired hemophilia A (AHA), a rare bleeding disorder, have a new treatment, as the Food and Drug Administration (FDA) has approved Baxter’s Obizur.

  8. Celgene Partners With Sutro On ADCs, Acquires Option To Buy Sutro
    10/29/2014

    Celgene Corporation has expanded its partnership with Sutro Biopharma and has obtained an exclusive option to acquire Sutro.

  9. TAP Biosystems And Merck & Co., Inc. Double Triumph At BPI 2014 Awards
    10/28/2014

    Sartorius Stedim Biotech (SSB) recently announced that TAP Biosystems, part of SSB Group since 2013, and Merck & Co., Inc. have won two awards at the prestigious 2014 BioProcess International (BPI) Awards.

  10. J&J Joins Race To Develop And Deliver Ebola Vaccine
    10/28/2014

    Johnson & Johnson announced that it is committing up to $200 million to speed and expand its production of an Ebola vaccine under development at its subsidiary Janssen Pharmaceuticals.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.